03:44 AM EDT, 06/04/2025 (MT Newswires) -- Merus (MRUS) said Wednesday it priced an underwritten public offering of about 5.3 million common shares at $57 per share for expected gross proceeds of about $300 million.

The underwriters have been granted a 30-day option to purchase up to 789,473 additional shares.

Net proceeds will be used to fund clinical development, preclinical research and technology development, working capital and general corporate purposes.

Closing of the offering is expected on Thursday, subject to customary conditions.